Connect public, paid and private patent data with Google Patents Public Datasets

Treatment of nicotine craving and/or smoking withdrawal symptoms

Download PDF

Info

Publication number
US5599554A
US5599554A US08619860 US61986096A US5599554A US 5599554 A US5599554 A US 5599554A US 08619860 US08619860 US 08619860 US 61986096 A US61986096 A US 61986096A US 5599554 A US5599554 A US 5599554A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
caffeine
nicotine
mg
invention
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08619860
Inventor
Satyanarayana Majeti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/81Addiction
    • Y10S514/813Tobacco

Abstract

The subject invention encompasses a transdermally or transmucosally administrable composition for the treatment or nicotine craving or smoking withdrawal symptoms comprising nicotine and caffeine or caffeine equivalent.

Description

This is a continuation of application Ser. No. 08/264,654, filed on Jun. 23, 1994, now abandoned.

BACKGROUND OF THE INVENTION

The health hazards from smoking tobacco are well known. Of the many by-products of combustion found in cigarette smoke, the substances most studied have been tars, carbon monoxide, and nicotine. Tars are the agents linked to the causation of various cancers and pulmonary diseases such as emphysema and chronic bronchitis. Carbon monoxide is a deadly gas which reduces the ability of blood hemoglobin to carry sufficient oxygen. Carbon monoxide has also been causally linked to coronary artery disease and atherosclerosis. Nicotine appears to be the most pharmacologically active substance in tobacco smoke, yet it seems not to be as significant from a health standpoint as the tars and carbon monoxide. However, nicotine is the reinforcing substance in tobacco which maintains the addiction.

Various efforts have been made by smokers to discontinue smoking. Chewing beeswax, eating candy and peppermints, as well as cold turkey interruption have been tried without much success. The addition of chemicals designed to sicken the user or otherwise render smoking repulsive to the user have also not produced good results. More recent therapies for smoking cessation have focused on the administration of nicotine to the smoker. These therapies allow the individual to satisfy a nicotine habit while minimizing or eliminating side effects caused by absorbing nicotine through the lungs along with the other harmful by-products of combustion of tobacco.

Nicotine supplementation has proven to be an effective therapy as an adjunct to smoking cessation in helping to reduce the craving for smoking and provide relief from smoking withdrawal symptoms. However, there are many smokers for whom nicotine supplementation alone is inadequate. In accordance with the present invention, it has been discovered that a composition can be formulated which provides the combination of nicotine and caffeine or caffeine equivalent in a single therapy. It has also been discovered that such a combination may offer the advantage of providing treatment and/or relief of nicotine craving and/or smoking withdrawal symptoms to a broader spectrum of smokers who wish to break the smoking habit. It has further been discovered that these compositions may also curb the appetite which may aid in reducing the weight gain that is commonly experienced by individuals who stop smoking.

It is an object of the present invention to provide a composition comprising the combination of nicotine and caffeine or caffeine equivalent in a single therapy. It is also an object of the present invention to deliver the nicotine and caffeine combination therapy in a convenient delivery system. It is a further object of the invention to provide a method for the treatment and/or relief of nicotine craving and/or smoking withdrawal symptoms in individuals who wish to break or decrease the habit of smoking tobacco or the use of any tobacco product. These and other objects will become readily apparent from the detailed description which follows.

SUMMARY OF THE INVENTION

The present invention relates to a transdermally or transmucosally administrable composition for the treatment of nicotine craving and/or smoking withdrawal symptoms comprising nicotine and caffeine or caffeine equivalent, wherein the composition delivers from about 1 mg to about 100 mg of nicotine, and from about 10 mg to about 250 mg of caffeine or caffeine equivalent.

The present invention also relates to a method for providing treatment and/or relief of nicotine craving and/or smoking withdrawal symptoms to a human or lower animal in need of such treatment comprising the administration of a safe and effective amount of a transdermally or transmucosally administrable composition comprising nicotine and caffeine or caffeine equivalent.

DETAILED DESCRIPTION OF THE INVENTION

The subject invention comprises nicotine, caffeine or caffeine equivalent, and preferably one or more pharmaceutically-acceptable carriers suitable for transdermal and/or transmucosal administration. These compositions are useful for the treatment and/or relief of nicotine craving and/or smoking withdrawal symptoms.

The terms "nicotine craving" and "smoking withdrawal symptoms" as used herein both refer to any physical or psychological reaction relating to breaking the habit of smoking tobacco or using any tobacco product or decreasing the frequency or intensity of smoking tobacco or using any tobacco product.

In general, the descriptive term "pharmaceutically-acceptable" is used herein to describe materials that are non-toxic and suitable for administration to humans and/or lower animals. The term "pharmaceutically-acceptable carder" as used herein means any material safe and effective for use in the compositions of the present invention. Such materials include pH adjusters, emollients, emulsifiers, buffering agents, solvents, preservatives, pressure-sensitive adhesive foming polymers, film forming polymers, bioadhesive and mucoadhesive polymers, water, wetting agents, thickeners, plasticizers, disintegration agents, humectants, surfactants, aromatic compounds, agents for aiding the film-forming properties and substantivity of the formulations, antimicrobials for maintaining the antimicrobial integrity of the compositions, antioxidants, agents suitable for aesthetic purposes such as fragrances, pigments, and colorings, non-soluble ingredients, any material suitable or transdermal or transmucosal carriers, and mixtures thereof.

The terms "safe and effective amount", as used herein, mean a sufficient amount of material to provide the desired benefit without undue adverse side effects commensurate with a reasonable benefit/risk ratio when used in the manner of this invention. The specific safe and effective amount will vary with such factors as the particular condition that is being treated, the severity of the condition, the duration of the treatment, the physical condition of the patient, the nature of concurrent therapy (if any), and the specific formulation and optional components hereinafter.

The terms "suitable for transdermal and/or transmucosal administration" and "transdermally or transmucosally administrable", as used herein, refer to any composition or formulation that is suitable for the convenient administration of the composition whereby the nicotine and caffeine or caffeine source is absorbed through the skin or oral mucosa.

The following terms will be designated as follows: milligram as "mg", milliliter as "ml", nanogram as "ng", and microgram as "ug".

A detailed description of essential and optional components of the present invention is given below.

Nicotine

The present invention comprises nicotine. Nicotine is a tertiary amine composed of a pyridine and a pyrrolidine ring. It is a colorless to pale yellow, which is freely water soluble, strongly alkaline, hygroscopic liquid obtained from the tobacco plant. Nicotine has a characteristic odor and turns brown on exposure to air or light [Physicians Desk Reference, 48th Edition, p. 1306, 1984] Nicotine is delivered in an amount of from about 1 mg to about 100 mg, preferably from about 5 mg to about 75 mg, and most preferably from about 10 mg to about 50 mg. Nicotine is also described in Remington's Pharmaceutical Sciences, 18th Edition, 1990, p. 891, which is incorporated herein by reference.

Caffeine

The present inventions also comprise caffeine or a caffeine equivalent. Caffeine is found as white, fleecy masses or long, flexible, silky crystals. It is odorless, bitter tasting, and slightly soluble in water and alcohol. Caffeine may be derived synthetically or by extraction of coffee beans, tea leaves or kola nuts [Hawley's Condensed Chemical Dictionary, Twelfth Edition, 1993]. Examples of suitable sources of caffeine for use in the present invention are pure caffeine, caffeine combined with acetate, citrate, benzoate, phosphate, sulfate or salicylate. Also suitable are any of the xanthine analogues that match caffeine's effectiveness as a central nervous system stimulant, including salts thereof that are compatible. Xanthine derivatives are described in Reminton's Pharmaceutical Sciences, 18th Edition, 1990, pp. 1132-34, which is incorporated herein by reference. The caffeine or caffeine equivalent is delivered in an amount of from about 10 mg to about 250 mg, preferably from about 50 mg to about 200 mg, and most preferably from about 75 mg to about 100 mg.

Pharmaceutically-Acceptable Aqueous Carrier

The invention compositions preferably also contain one or more pharmaceutically-acceptable carriers suitable for transdermal and/or transmucosal administration. Such compositions include (but are not limited to) transdermal and buccal patches, bioadhesive and mucoadhesive films or other formulations suitable administering the present compositions transdermally and/or transmucosally.

The present compositions also include formulations which deliver the nicotine and/or caffeine or caffeine equivalent in a sustained release system or at varying intervals or levels throughout the transdermal or transmucosal administration of the composition. Transdermal drug delivery systems are fully described in Pharmaceutical Dosage Forms and Drug Delivery Systems, Howard C. Ansel, Ph.D. and Nicholas G. Popovich, Ph.D., Fifth Edition, 1990, pp. 310-320, U.S. Pat. No. 3,598,122, to Zaffaroni, issued Aug. 10, 1971, and U.S. Pat. No. 4,713,243, to Schiraldi, et. al., issued Dec. 15, 1987, all of which is incorporated herein by reference.

While the choice of transdermal or transmucosal carrier is not critical to the present invention, the carrier or carriers chosen must be suitable for administering the nicotine and caffeine or caffeine equivalent so that the desired blood levels of these compounds are achieved in the body of the recipient. The desired blood level of nicotine is from about 1 ng/ml to about 100 ng/ml, preferably from about 5 ng/ml to about 75 ng/ml, and most preferably from about 10 ng/ml to about 50 ng/ml, preferably within 1 to 4 hours of administration. The desired blood level of caffeine or caffeine equivalent is from about 0.01 ug/ml to about 20 ug/ml, preferably from about 0.1 ug/ml to about 15 ug/ml, and most preferably from about 0.5 ug/ml to about 10 ug/ml, preferably within 1-4 hours of administration.

The present compositions will normally be prepared in dosage unit form to contain safe and effective amounts of the nicotine and caffeine (or equivalent) to achieve the desired blood levels. Fractions of the dosage units or multiple dosage units may also be utilized. In general, the transdermally or transmucosally administrable compositions deliver to a human or lower animal from about 1 mg to about 100 mg, preferably from about 5 mg to about 75 mg, and most preferably from about 10 mg to about 50 mg of nicotine; and from about 10 mg to about 250 mg, preferably from about 50 mg to about 200 mg, and most preferably from about 75 mg to about 100 mg, of caffeine or caffeine equivalent. Preferably, the present invention may be a transdermally or transmucosally administrable composition for the treatment of nicotine craving and/or smoking withdrawal symptoms comprising nicotine, caffeine or caffeine equivalent, and one or more pharmaceutically-acceptable carders suitable for transdermal or transmucosal administration, wherein the composition delivers from about 1 mg to about 100 mg of nicotine, and from about 10 mg to about 250 mg of caffeine or caffeine equivalent.

The amount of nicotine and caffeine or caffeine equivalent and frequency of administration may vary depending on the carrier chosen and the personal needs of the user. However, it is suggested (as an example) that the present invention be administered from about once per day to once per week, preferably from about once per day to about 3 times per week, and most preferably about once per day.

The transdermal or transmucosal carriers of the present invention may comprise a single layer or multi-layer system. Typically these carriers comprise an adhesive layer, which in a single layer system, releases the nicotine and caffeine or caffeine equivalent. The adhesive layer may be mucoadhesive, bioadhesive, pressure sensitive or require moisture for adhesion. Multi-layer systems generally will also comprise at least one reservoir layer, a backing component, and may include other layers of varying solubility which aid in controlling the release rate of actives being administered.

Any of the dermatologically acceptable pressure-sensitive adhesives which permit drug migration can be used in the present compositions. Exemplary adhesives include acrylic resins such as polymers of esters of acrylic acid with alcohols (not limited to) n-butanol, n-pentanol, isopentanol, 2-methyl butanol, 2-methyl pentanol, or n-decanol, alone or copolymerized with ethylenically unsaturated monomers such as acrylic acid, methacrylic acid, glycol diacrylates, or mixtures thereof; elastomeric silicone polymers; polyurethane elastomers; rubbery polymers; vinyl polymers such as polyvinylalcohol, polyvinyl pyrrolidone, and polyvinylacetate; cellulose derivatives such as ethyl cellulose, methyl cellulose and carboxymethyl cellulose; natural gums such as guar, acacia, pectins, and the like; and mixtures thereof. Preferred for use in with the oral mucosa are rubbery polymers such as polyisobutylene, with or without gum modifiers, polyvinyl alcohol, polyvinyl pyrrolidone, cellulose derivatives, and mixtures thereof.

Water soluble or water swellable polymers may comprise the adhesive layer to create a bioadhesive or mucoadhesive film. Suitable polymers include hydroxypropyl cellulose, polyethylene oxide homopolymers, alkyl or polyvinyl ethermaleic maleic acid copolymers, polyacrylic acid, polyvinylpyrrolidone, and mixtures thereof. An exemplary adhesive layer which adheres to wet mucosal surfaces comprises from about 40% to about 95% of hydroxypropyl cellulose, from about 5% to about 60% of a homopolymer of ethylene oxide, and from about 2% to about 10% of a glycol plasticizer. The adhesive layer will generally have a thickness of from about 0.01 millimeters to about 7 millimeters, though such limits are not critical to the practice of the present invention.

The compositions of the present invention may also contain a reservoir layer. The reservoir layer may be formed by materials capable of forming film walls or matrixes which allow the nicotine and caffeine or caffeine equivalent to pass by diffusion. Materials for use in a reservoir layer include without limitation: silicone rubbers such as conventional heat-curable silicones or room temperature vulcanizable silicone rubbers, poly(hydroxyethylacrylate) and poly (hydroxyethylmethacrylate), polyvinylalcohol, polyvinylacetate, plasticized polyvinylchloride, polyvinylpyrrolidone plus mannitol, plasticized nylon, collagen, gelatin, waxes such as polyethylene wax, oxidized polyethylene wax, hydrogenated castor oil, and the like.

The present inventions may also contain a backing component to prevent the passage of the drug through surface of the delivery vehicle opposite the skin or oral mucosa. The backing member component can be flexible or nonflexible. Materials useful as the backing component include cellophane, cellulose acetate, cellulose acetate isobutyrate, cellulose acetate propionate, ethylcellulose, plasticized vinylacetate-vinylchloride copolymers, polyethylene terephthalate, nylon, polyethylene, polyurethanes, rubber based polyisobutylene, styrene, and styrene-butadiene copolymers, polyvinylidene chloride, and the like. If the outer surface of the reservoir layer is durable enough and impermeable to the nicotine and caffeine or caffeine equivalent, the backing component may be unnecessary.

Various polymers may be incorporated into one or more of the transdermal or transmucosal carriers to modify one or more of the layer's permeability thereby effecting the amount or rate of delivery of the nicotine and/or caffeine (or caffeine equivalent). Useful polymers for modifying permeability include ethyl cellulose, propyl cellulose, polyethylene, polypropylene, carboxymethylcellulose (free acid), and mixtures thereof.

The present compositions may contain one or more solvents. Suitable solvents include but are not limited to water, alcohol, propylene glycol, glycerin, sorbitol solution and the like, to assist solubilization and incorporation of water-insoluble ingredients.

The present compositions may also contain a plasticizer. Suitable plasticizers include glycols such as propylene glycol and polyethylene glycol; polyhydric alcohols such as glycerin and sorbitol, glycerol esters such as glycerol triacetate; fatty acid triglycerides such as NEOBEE M-5 and MYVEROLS; distilled acetylated monoglycerides; sucrose acetate isobutyrate; triacetin; mineral oil; vegetable oils; and mixtures thereof. Preferred plasticizers are triacetin, propylene glycol or polyethylene glycol.

A pharmaceutically-acceptable preservative may be employed to increase the shelf life of the compositions. Benzyl alcohol is suitable, although a variety of preservatives including, for example, parabens, thimerosal, chlorobutanol, phenylmercuric acetate or benzalkonium chloride may also be employed. The most preferred preservatives for use herein include benzalkonium chloride, chlorhexidine gluconate, butylated hydroxy toluene, and disodium EDTA. A suitable concentration of the preservative will be from about 0.001% to about 2% based on the total weight, although there may be appreciable variation depending upon the agent selected.

The compositions of the present invention also include microencapsulation of either the nicotine or caffeine (or caffeine equivalent) or both. Techniques and materials for microencapsulation are well known in the art. Microencapsulation is discussed more fully in Kirk and Othmer's Encyclopedia of Chemical Technology, Vol. 13, 2nd Edition, pp. 436-456, which is incorporated herein by reference.

The compositions of the present invention may also contain one or more aromatic components. These aromatics include, for example, menthol, eucalyptol, benzaldehyde (cherry, almond); citral (lemon, lime); neral; decanal (orange, lemon); aldehyde C-8, aldehyde C-9 and aldehyde C-12 (citrus fruits); tolyl aldehyde (cherry, almond); 2,6-dimethyl-octanal (green fruit); 2-dodecenal (citrus, mandarin); thymol; cedar leaf oil, myristica oil, lavender oil, nutmeg oil, turpentine; 3-1-menthoxy propane- 1,2-diol; N-substituted-p-menthane-3-carbox-amides and acyclic carboxamides; and mixtures thereof. Preferred are menthol, eucalyptol, thymol, cedar leaf oil, myristica oil, lavender oil, nutmeg oil, turpentine, and mixtures thereof. Aromatic compounds may be present at a level of from about 0.0001% to about 1%, preferably from about 0.001% to about 1%, and most preferably from about 0.001% to about 0.5%, by weight of the compositions.

A variety of additional optional pharmaceutically-acceptable ingredients may also be added to the present invention compositions. These additional ingredients include pH adjusters such as sodium hydroxide; fillers; disintegration agents such as magnesium silicate, calcium carbonate, stearic acid and its salts, palmitic acid; emulsifiers; binders; dispersants; thickeners; buffering agents such as sodium bicarbonate; various polymers for aiding the film-forming properties and substantivity of the formulations; antimicrobials for maintaining the antimicrobial integrity of the compositions; antioxidants; and agents suitable for aesthetic purposes such as fragrances, pigments, and colorings.

Method of Treatment

The present invention also encompasses a method of treatment. The method of providing treatment and/or relief of nicotine craving and/or smoking withdrawal symptoms to a human or lower animal in need of such treatment, as disclosed herein, comprises the administration of a safe and effective amount of a transdermally or transmucosally administrable composition comprising nicotine and caffeine or caffeine equivalent. Such compositions preferably further comprise one or more pharmaceutically acceptable carriers suitable for transdermal or transmucosal administration.

The following examples further describe and demonstrate embodiments within the scope of the present invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention.

EXAMPLE I

A single layer transdermal delivery system according to the present invention may be prepared as follows:

______________________________________Ingredient          Weight %______________________________________Ethylene Oxide Homopolymer               57.9(Polyox WSR-301)Hydroxypropyl Cellulose               26.0(Klucel MF)Polyethylene (AC-6A)               5.0Propylene Glycol    3.0Polyethylene Glycol 400               2.0Butylated Hydroxy Toluene               0.1Caffeine            4.0Nicotine            2.0______________________________________

The above ingredients are prepared according to methods known in the art.

EXAMPLE II

A multi-layer buccal dosage form according to the present invention may be prepared as follows:

______________________________________         Weight % in Each LayerIngredient      Drug Reservoir                       Adhesive Barrier______________________________________Titanium Dioxide            5.0Sucrose Acetate Isobutyrate 3.5Alginic Acid    14.0Flavoring       10.0Cellulose Acetate Butyrate           6.5         17.5     5.0Polycarbophil.sup.1                  7.0Polyvinyl Pyrrolidone           4.0Polyethylene Glycol 800              2.5Guar Gum                             7.0Caffeine        5.0Nicotine        1.0Triacetin       4.0                  5.0Solvent         55.5        74.0     73.5______________________________________ .sup.1 Carbopol ® from B. F. Goodrich Corp.

The above ingredients are prepared according to methods known in the art.

Claims (10)

What is claimed is:
1. A transdermally or transmucosally administrable composition for the treatment of nicotine craving or smoking withdrawal symptoms comprising nicotine, caffeine or xanthine compounds, and one or more pharmaceutically-acceptable carriers suitable for transdermal or transmucosal administration selected from the group consisting of a transdermal patch, buccal patch, bioadhesive film, or mucoadhesive film, or combinations thereof, wherein the composition delivers:
a) from about 5 mg to about 100 mg of nicotine wherein the blood level of nicotine is from about 1 nanogram per milliliter to about 100 nanograms per milliliter; and
b) from about 10 mg to about 250 mg of caffeine or xanthine compounds wherein the blood level of caffeine or xanthine compounds is from about 0.01 microgram per milliliter to about 20 micrograms per milliliter.
2. The composition according to claim 1 wherein the composition is in the form of a multi-layer transdermal or transmucosal carrier comprising an adhesive layer and a reservoir layer.
3. The composition according to claim 2 wherein (b) is caffeine.
4. The composition according to claim 1 comprising:
a) from about 5 mg to about 75 mg of nicotine; and
b) from about 50 mg to about 200 mg of caffeine or xanthine compounds.
5. The composition according to claim 4 further comprising a pressure-sensitive adhesive layer.
6. The composition according to claim 5 wherein the composition is in the form of a multi-layer transdermal carrier comprising a reservoir layer, and a backing component.
7. The composition according to claim 6 wherein the composition is in the form of a multi-layer transmucosal carrier.
8. The composition according to claim 7 further comprising from about 0.01% to about 5% of one or more flavorings.
9. A method for providing treatment of nicotine craving and smoking withdrawal symptoms to a human or lower animal in need of such treatment comprising the administration of a safe and effective amount of the transdermally or transmucosally administrable composition according to claim 1.
10. A method for providing relief of nicotine craving and smoking withdrawal symptoms in a human or lower animal in need of such treatment comprising the administration of a safe and effective amount of the transdermally or transmucosally administrable composition according to claim 4.
US08619860 1994-06-23 1996-03-19 Treatment of nicotine craving and/or smoking withdrawal symptoms Expired - Fee Related US5599554A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US26465494 true 1994-06-23 1994-06-23
US08619860 US5599554A (en) 1994-06-23 1996-03-19 Treatment of nicotine craving and/or smoking withdrawal symptoms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08619860 US5599554A (en) 1994-06-23 1996-03-19 Treatment of nicotine craving and/or smoking withdrawal symptoms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US26465494 Continuation 1994-06-23 1994-06-23

Publications (1)

Publication Number Publication Date
US5599554A true US5599554A (en) 1997-02-04

Family

ID=23007034

Family Applications (1)

Application Number Title Priority Date Filing Date
US08619860 Expired - Fee Related US5599554A (en) 1994-06-23 1996-03-19 Treatment of nicotine craving and/or smoking withdrawal symptoms

Country Status (2)

Country Link
US (1) US5599554A (en)
WO (1) WO1996000072A1 (en)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US5935604A (en) * 1993-05-20 1999-08-10 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine
DE19913732A1 (en) * 1999-03-26 2000-09-28 Lohmann Therapie Syst Lts Nicotine TTS with an addition of monoterpene ketones
US6166032A (en) * 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US20020162563A1 (en) * 2001-05-01 2002-11-07 Williams Jonnie R. Smokeless tobacco product
US20030068376A1 (en) * 2001-04-20 2003-04-10 Lavipharm Laboratories Inc. Intraoral delivery of nicotine for smoking cessation
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6562368B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US6562369B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6565879B1 (en) 1999-12-16 2003-05-20 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6592887B2 (en) 1996-11-11 2003-07-15 Lts Lohmann Therapie-Systeme Ag Water soluble film for oral administration with instant wettability
US6645520B2 (en) 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US6668839B2 (en) 2001-05-01 2003-12-30 Jonnie R. Williams Smokeless tobacco product
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US20040020503A1 (en) * 2001-05-01 2004-02-05 Williams Jonnie R. Smokeless tobacco product
WO2004064811A1 (en) * 2003-01-24 2004-08-05 Magle Holding Ab A composition material for transmucosal delivery
US20040191322A1 (en) * 2002-12-20 2004-09-30 Henri Hansson Physically and chemically stable nicotine-containing particulate material
US20040220262A1 (en) * 1999-12-16 2004-11-04 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20040224007A1 (en) * 2003-05-09 2004-11-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US20040234585A1 (en) * 1998-12-18 2004-11-25 Gale Robert M. Transparent transdermal nicotine delivery devices
US20050147658A1 (en) * 1996-10-18 2005-07-07 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US20050186257A1 (en) * 2004-02-20 2005-08-25 Todd Manegold Dissolvable film and method of manufacture
US20050244521A1 (en) * 2003-11-07 2005-11-03 Strickland James A Tobacco compositions
US20060013864A1 (en) * 2002-11-08 2006-01-19 Hans-Rainer Hoffmann Transmucosal pharmacuetical administration form
US20060039959A1 (en) * 2002-06-14 2006-02-23 Werner Wessling Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents
US20060073189A1 (en) * 2000-05-19 2006-04-06 Npd, Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
US20060147498A1 (en) * 2003-01-24 2006-07-06 Ingemar Jonsson Composition material for transmucosal delivery
US20060191548A1 (en) * 2003-11-07 2006-08-31 Strickland James A Tobacco compositions
US20060198873A1 (en) * 2003-07-24 2006-09-07 Chan Shing Y Orally dissolving films
US7105173B1 (en) 2002-03-21 2006-09-12 Rolling Kenneth J Nicotine replacement applique
US20070014887A1 (en) * 1998-09-03 2007-01-18 Cherukuri Subraman R Medicated chewing gum delivery system for nicotine
US20070042023A1 (en) * 2005-08-22 2007-02-22 National Starch And Chemical Investment Holding Corporation Dissolvable film
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US20080103111A1 (en) * 2006-06-21 2008-05-01 Harlan Clayton Bieley Smoking Cessation Treatment with Appetite Suppression
US20090221489A1 (en) * 2005-12-23 2009-09-03 Kjell Stenberg Water-Soluable Films Comprising Low-Viscosity Alginates
US20100021570A1 (en) * 2006-06-21 2010-01-28 Harlan Clayton Bieley Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke
US20110014277A1 (en) * 2006-06-21 2011-01-20 Harlan Clayton Bieley Smoking Cessation With Body Weight Maintenance And Nutritional Supplement
CN1741791B (en) 2003-01-24 2011-11-16 美格乐控股公司 A composition material for transmucosal delivery
US8703177B2 (en) 2011-08-18 2014-04-22 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
US9597288B2 (en) 2006-07-21 2017-03-21 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746644A1 (en) * 1996-03-18 1997-10-03 Firion Jackie Powders containing L-phenyl alanine and plant extracts
WO1998003175A1 (en) * 1996-07-18 1998-01-29 International Diabetes Institute Treatment of obesity
US6465004B1 (en) 1999-06-05 2002-10-15 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
DE10018834A1 (en) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound
JP5089840B2 (en) * 2001-09-25 2012-12-05 救急薬品工業株式会社 Nicotine-containing film preparation
WO2007095600A3 (en) * 2006-02-17 2008-04-17 Novartis Ag Disintegrable oral films
GB0611225D0 (en) * 2006-06-07 2006-07-19 Marshall Paul Transdermal patch
DE102006027795A1 (en) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Smoking cessation combination wafer
EP2134321A2 (en) 2007-03-07 2009-12-23 Novartis Ag Orally administrable films

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
EP0192950A1 (en) * 1985-02-23 1986-09-03 Hans-Josef Stromberg Device for breaking the habit of eating, drinking, smoking and/or other manias
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US4713243A (en) * 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4778677A (en) * 1981-07-09 1988-10-18 Ebbesen Gerald K Method for treatment of nicotine craving
US4806356A (en) * 1983-06-29 1989-02-21 Shaw Alec S W Tobacco product
US4863737A (en) * 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4883660A (en) * 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US4900552A (en) * 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US4929508A (en) * 1984-10-05 1990-05-29 Warner-Lambert Company Novel drug delivery system for antitussives
US4959380A (en) * 1988-12-19 1990-09-25 Wilson Jordan E Method of treating people to stop smoking and composition
US4980169A (en) * 1990-05-03 1990-12-25 Warner-Lambert Company Flavor enhancing and increasing efficacy of cough drops
WO1991003998A1 (en) * 1989-09-14 1991-04-04 Cygnus Research Corporation Transdermal delivery device having delayed onset
US5051426A (en) * 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency
EP0563507A1 (en) * 1992-04-01 1993-10-06 Mli Acquisition Corp. Ii Transdermal patch incorporating a polymer film incorporated with an active agent
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5298501A (en) * 1991-03-25 1994-03-29 Valent U.S.A. Corporation Chemically stable granules containing insecticidal phosphoroamidothioates

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122B1 (en) * 1969-04-01 1982-11-23
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4778677A (en) * 1981-07-09 1988-10-18 Ebbesen Gerald K Method for treatment of nicotine craving
US4806356A (en) * 1983-06-29 1989-02-21 Shaw Alec S W Tobacco product
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor
US4929508A (en) * 1984-10-05 1990-05-29 Warner-Lambert Company Novel drug delivery system for antitussives
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
EP0192950A1 (en) * 1985-02-23 1986-09-03 Hans-Josef Stromberg Device for breaking the habit of eating, drinking, smoking and/or other manias
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4863737A (en) * 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4713243A (en) * 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4900552A (en) * 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US4883660A (en) * 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US4959380A (en) * 1988-12-19 1990-09-25 Wilson Jordan E Method of treating people to stop smoking and composition
WO1991003998A1 (en) * 1989-09-14 1991-04-04 Cygnus Research Corporation Transdermal delivery device having delayed onset
US5051426A (en) * 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency
US4980169A (en) * 1990-05-03 1990-12-25 Warner-Lambert Company Flavor enhancing and increasing efficacy of cough drops
US5298501A (en) * 1991-03-25 1994-03-29 Valent U.S.A. Corporation Chemically stable granules containing insecticidal phosphoroamidothioates
EP0563507A1 (en) * 1992-04-01 1993-10-06 Mli Acquisition Corp. Ii Transdermal patch incorporating a polymer film incorporated with an active agent

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cohen, C., et al., "Caffeine Antagonizes EEG Effects of Tobacco Withdrawal", Pharmacology Biochemistry and Behavior, vol. 47, No. 4, pp. 919-926 (Apr., 1994).
Cohen, C., et al., Caffeine Antagonizes EEG Effects of Tobacco Withdrawal , Pharmacology Biochemistry and Behavior, vol. 47, No. 4, pp. 919 926 (Apr., 1994). *
Tariq, M., et al., "Effect of Nicotine and Caffeine Pretreatment on the Gastric Mucosal Damage Induced by Aspirin, Phenylbutazone, and Reserpine in Rats", Toxicology and Applied Pharmacology, vol. 79, No. 2, pp. 268-273 (Jun. 30, 1985).
Tariq, M., et al., Effect of Nicotine and Caffeine Pretreatment on the Gastric Mucosal Damage Induced by Aspirin, Phenylbutazone, and Reserpine in Rats , Toxicology and Applied Pharmacology, vol. 79, No. 2, pp. 268 273 (Jun. 30, 1985). *
Wilson, Steven P., "Pertussis Toxin Enhances Proenkephalin Synthesis in Bovine Chromaffin Cells", Journal of Neurochemistry, vol. 61, No. 5, pp. 1901-1906 (Nov., 1993).
Wilson, Steven P., Pertussis Toxin Enhances Proenkephalin Synthesis in Bovine Chromaffin Cells , Journal of Neurochemistry, vol. 61, No. 5, pp. 1901 1906 (Nov., 1993). *

Cited By (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935604A (en) * 1993-05-20 1999-08-10 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine
US20050147658A1 (en) * 1996-10-18 2005-07-07 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US7579019B2 (en) * 1996-10-18 2009-08-25 Arius Two, Inc. Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US6709671B2 (en) 1996-11-11 2004-03-23 Lts Lohmann Therapie-Systeme Ag Water soluble film for oral administration with instant wettability
US8865202B2 (en) 1996-11-11 2014-10-21 Lts Lohmann Therapie-Systeme Ag Water soluble film for oral administration with instant wettability
US20040156885A1 (en) * 1996-11-11 2004-08-12 Zerbe Horst Georg Water soluble film for oral administration with instant wettability
US6592887B2 (en) 1996-11-11 2003-07-15 Lts Lohmann Therapie-Systeme Ag Water soluble film for oral administration with instant wettability
US6166032A (en) * 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6893654B2 (en) 1998-09-03 2005-05-17 Jsr, Llc Two-stage transmucosal medicine delivery system for symptom relief
US20050214229A1 (en) * 1998-09-03 2005-09-29 Jsr, Llc Two-stage transmucosal medicine delivery system for symptom relief
US20070014887A1 (en) * 1998-09-03 2007-01-18 Cherukuri Subraman R Medicated chewing gum delivery system for nicotine
US8075911B2 (en) 1998-12-18 2011-12-13 Alza Corporation Transparent transdermal nicotine delivery devices
US9205059B2 (en) 1998-12-18 2015-12-08 Alza Corporation Transparent transdermal nicotine delivery devices
US20040234585A1 (en) * 1998-12-18 2004-11-25 Gale Robert M. Transparent transdermal nicotine delivery devices
US8999379B2 (en) 1998-12-18 2015-04-07 Alza Corporation Transparent transdermal nicotine delivery devices
US8663680B2 (en) 1998-12-18 2014-03-04 Alza Corporation Transparent transdermal nicotine delivery devices
EP2158903A2 (en) 1998-12-18 2010-03-03 ALZA Corporation Transparent Transdermal Nicotine Delivery Devices
US7622136B2 (en) 1998-12-18 2009-11-24 Alza Corporation Transparent transdermal nicotine delivery devices
JP4750282B2 (en) * 1999-03-26 2011-08-17 エルテーエス ローマン テラピー−ジステーメ アーゲー Transdermal therapeutic system of nicotine with the addition of monoterpene ketone
WO2000057824A1 (en) * 1999-03-26 2000-10-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with nicotine and addition of monoterpene ketones
DE19913732A1 (en) * 1999-03-26 2000-09-28 Lohmann Therapie Syst Lts Nicotine TTS with an addition of monoterpene ketones
US7029692B1 (en) * 1999-03-26 2006-04-18 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with nicotine and addition of monoterpene ketones
US6562368B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US20030224035A1 (en) * 1999-12-16 2003-12-04 Luo Eric C. Hydroxide-releasing agents as skin permeation enhancers
US6562369B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US20030147943A1 (en) * 1999-12-16 2003-08-07 Luo Eric C. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6645520B2 (en) 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US20030161870A1 (en) * 1999-12-16 2003-08-28 Tsung-Min Hsu Dual enhancer composition for topical and transdermal drug delivery
US20030157156A1 (en) * 1999-12-16 2003-08-21 Tsung-Min Hsu Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US20040220262A1 (en) * 1999-12-16 2004-11-04 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20030129220A1 (en) * 1999-12-16 2003-07-10 Luo Eric C. Transdermal administration of androgenic drugs using hydroxide-releasing agents as permeation enhancers
US20090317453A1 (en) * 1999-12-16 2009-12-24 Dermatrends, Inc. Transdermal and topical administration of drugs using basic permeation enhancers
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6835392B2 (en) 1999-12-16 2004-12-28 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6565879B1 (en) 1999-12-16 2003-05-20 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US20060093659A1 (en) * 1999-12-16 2006-05-04 Luo Eric C Hydroxide-releasing agents as skin permeation enhancers
US20060073189A1 (en) * 2000-05-19 2006-04-06 Npd, Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
US20070298090A1 (en) * 2001-04-20 2007-12-27 Lavipharm Laboratories, Inc. Intraoral delivery of nicotine for smoking cessation
US20030068376A1 (en) * 2001-04-20 2003-04-10 Lavipharm Laboratories Inc. Intraoral delivery of nicotine for smoking cessation
EP1389910A1 (en) * 2001-04-20 2004-02-25 Lavipharm Laboratories, Inc. Intraoral delivery of nicotine for smoking cessation
EP1389910A4 (en) * 2001-04-20 2005-11-02 Lavipharm Lab Inc Intraoral delivery of nicotine for smoking cessation
US20040020503A1 (en) * 2001-05-01 2004-02-05 Williams Jonnie R. Smokeless tobacco product
US20020162563A1 (en) * 2001-05-01 2002-11-07 Williams Jonnie R. Smokeless tobacco product
US6668839B2 (en) 2001-05-01 2003-12-30 Jonnie R. Williams Smokeless tobacco product
US6834654B2 (en) 2001-05-01 2004-12-28 Regent Court Technologies, Llc Smokeless tobacco product
US7105173B1 (en) 2002-03-21 2006-09-12 Rolling Kenneth J Nicotine replacement applique
US20060039959A1 (en) * 2002-06-14 2006-02-23 Werner Wessling Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings
US20060013864A1 (en) * 2002-11-08 2006-01-19 Hans-Rainer Hoffmann Transmucosal pharmacuetical administration form
US9629832B2 (en) 2002-12-20 2017-04-25 Niconovum Usa, Inc. Physically and chemically stable nicotine-containing particulate material
US8741348B2 (en) 2002-12-20 2014-06-03 Niconovum Ab Physically and chemically stable nicotine-containing particulate material
US20040191322A1 (en) * 2002-12-20 2004-09-30 Henri Hansson Physically and chemically stable nicotine-containing particulate material
JP2006516567A (en) * 2003-01-24 2006-07-06 マグル ホールディング エービー Transmucosal transmitting composition material
WO2004064811A1 (en) * 2003-01-24 2004-08-05 Magle Holding Ab A composition material for transmucosal delivery
US8846075B2 (en) * 2003-01-24 2014-09-30 Magle Holding Ab Composition material for transmucosal delivery
US20060147498A1 (en) * 2003-01-24 2006-07-06 Ingemar Jonsson Composition material for transmucosal delivery
CN1741791B (en) 2003-01-24 2011-11-16 美格乐控股公司 A composition material for transmucosal delivery
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US20040224007A1 (en) * 2003-05-09 2004-11-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US9675548B2 (en) 2003-07-24 2017-06-13 GlaxoSmithKline, LLC Orally dissolving films
US20060198873A1 (en) * 2003-07-24 2006-09-07 Chan Shing Y Orally dissolving films
US20090133704A1 (en) * 2003-11-07 2009-05-28 Strickland James A Tobacco Compositions
US20060191548A1 (en) * 2003-11-07 2006-08-31 Strickland James A Tobacco compositions
US8469036B2 (en) 2003-11-07 2013-06-25 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US8636011B2 (en) 2003-11-07 2014-01-28 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US20050244521A1 (en) * 2003-11-07 2005-11-03 Strickland James A Tobacco compositions
US20090133703A1 (en) * 2003-11-07 2009-05-28 Strickland James A Tobacco compositions
US20050186257A1 (en) * 2004-02-20 2005-08-25 Todd Manegold Dissolvable film and method of manufacture
US20070042023A1 (en) * 2005-08-22 2007-02-22 National Starch And Chemical Investment Holding Corporation Dissolvable film
US8759282B2 (en) 2005-12-23 2014-06-24 Uppsalagruppen Medical Ab Water-soluble films comprising low-viscosity alginates
US20090221489A1 (en) * 2005-12-23 2009-09-03 Kjell Stenberg Water-Soluable Films Comprising Low-Viscosity Alginates
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
US20100021570A1 (en) * 2006-06-21 2010-01-28 Harlan Clayton Bieley Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke
US20080103111A1 (en) * 2006-06-21 2008-05-01 Harlan Clayton Bieley Smoking Cessation Treatment with Appetite Suppression
US8889194B2 (en) 2006-06-21 2014-11-18 Harlan Clayton Bieley Smoking cessation with body weight maintenance and nutritional supplement
US20110014277A1 (en) * 2006-06-21 2011-01-20 Harlan Clayton Bieley Smoking Cessation With Body Weight Maintenance And Nutritional Supplement
US9597288B2 (en) 2006-07-21 2017-03-21 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US9655843B2 (en) 2006-07-21 2017-05-23 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US8956644B2 (en) 2006-11-03 2015-02-17 Durect Corporation Transdermal delivery systems
US8703177B2 (en) 2011-08-18 2014-04-22 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine

Also Published As

Publication number Publication date Type
WO1996000072A1 (en) 1996-01-04 application

Similar Documents

Publication Publication Date Title
US3667478A (en) Filter cigarette incorporating vitamin a
US6592887B2 (en) Water soluble film for oral administration with instant wettability
US5624677A (en) Controlled release of drugs delivered by sublingual or buccal administration
US6210699B1 (en) Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US4908389A (en) Penetration enhancement system
US6596740B2 (en) Nicotine mucosal spray
US4876092A (en) Sheet-shaped adhesive preparation applicable to oral cavity
Bruschi et al. Oral bioadhesive drug delivery systems
US20020019421A1 (en) Compositions and therapy for substance addiction
US5888534A (en) Controlled release of drugs delivered by sublingual or buccal administration
US6238689B1 (en) Intestinal absorption of nicotine to treat nicotine responsive conditions
US6770263B1 (en) Compositions and methods for the treatment of aches and pains
US20030022912A1 (en) Rapid-onset medicament for treatment of sexual dysfunction
US20060275344A1 (en) Flavoring of drug-containing chewing gums
US6319510B1 (en) Gum pad for delivery of medication to mucosal tissues
US4778810A (en) Nasal delivery of caffeine
Ìkinci et al. Development of a buccal bioadhesive nicotine tablet formulation for smoking cessation
US20020098264A1 (en) Medicated chewing gum delivery system for nicotine
US20010016593A1 (en) Element giving rapid release of nicotine for transmucosal administration
US6248760B1 (en) Tablet giving rapid release of nicotine for transmucosal administration
US20030206942A1 (en) Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent
US20030159702A1 (en) Formulation and use manufacture thereof
US6685951B2 (en) Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US6245353B1 (en) Solid, rapidly disintegrating cetirizine formulations
US5549906A (en) Nicotine lozenge and therapeutic method for smoking cessation

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Expired due to failure to pay maintenance fee

Effective date: 20050204